Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Olema Pharmaceuticals (OLMA) Shares Outstanding (Diluted Average) (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Shares Outstanding (Diluted Average) data on record, last reported at $102.8 million in Q1 2026.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 20.34% to $102.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $102.8 million, a 20.34% increase, with the full-year FY2025 number at $87.0 million, up 48.11% from a year prior.
  • Shares Outstanding (Diluted Average) reached $102.8 million in Q1 2026 per OLMA's latest filing, up from $87.0 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for OLMA hit a ceiling of $102.8 million in Q1 2026 and a floor of $39.8 million in Q1 2022.
  • A 5-year average of $59.1 million and a median of $55.6 million in 2024 define the central range for Shares Outstanding (Diluted Average).
  • Peak YoY movement for Shares Outstanding (Diluted Average): rose 1.08% in 2022, then surged 53.72% in 2025.
  • Tracing OLMA's Shares Outstanding (Diluted Average) over 5 years: stood at $40.0 million in 2022, then grew by 13.13% to $45.2 million in 2023, then grew by 29.83% to $58.7 million in 2024, then surged by 48.11% to $87.0 million in 2025, then rose by 18.15% to $102.8 million in 2026.
  • Business Quant data shows Shares Outstanding (Diluted Average) for OLMA at $102.8 million in Q1 2026, $87.0 million in Q4 2025, and $85.6 million in Q3 2025.